47583
Fmoc-Lys(Alloc)-OH
≥95.0% (HPLC), for peptide synthesis
别名:
Nα-芴甲氧羰基-Nε-烯丙氧羰基-L-赖氨酸
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H28N2O6
化学文摘社编号:
分子量:
452.50
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
NACRES:
NA.26
Beilstein/REAXYS Number:
5893081
MDL number:
产品名称
Fmoc-Lys(Alloc)-OH, ≥95.0% (HPLC)
SMILES string
OC(=O)[C@H](CCCCNC(=O)OCC=C)NC(=O)OCC1c2ccccc2-c3ccccc13
InChI
1S/C25H28N2O6/c1-2-15-32-24(30)26-14-8-7-13-22(23(28)29)27-25(31)33-16-21-19-11-5-3-9-17(19)18-10-4-6-12-20(18)21/h2-6,9-12,21-22H,1,7-8,13-16H2,(H,26,30)(H,27,31)(H,28,29)/t22-/m0/s1
InChI key
OJBNDXHENJDCBA-QFIPXVFZSA-N
assay
≥95.0% (HPLC)
form
powder
optical activity
[α]20/D −12±1°, c = 1% in DMF
reaction suitability
reaction type: Fmoc solid-phase peptide synthesis
technique(s)
NMR: suitable
color
beige
application(s)
peptide synthesis
functional group
Fmoc
storage temp.
2-8°C
Quality Level
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Petro P Czupiel et al.
Journal of controlled release : official journal of the Controlled Release Society, 305, 210-219 (2019-05-10)
Currently, there are limited treatment options for multi-drug resistant breast cancer. Lipid-modified cationic peptides have the potential to reach the mitochondria, which are attractive targets for the treatment of multi-drug resistant (MDR) breast cancer; yet, little is known about their
Mireia Hoyos-Nogués et al.
ACS applied materials & interfaces, 9(26), 21618-21630 (2017-06-09)
In dentistry and orthopedics, it is well accepted that implant fixation is a major goal. However, an emerging concern is bacterial infection. Infection of metallic implants can be catastrophic and significantly reduce patient quality of life. Accordingly, in this work
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持